Lobe Sciences Ltd.
LOBEF
$0.06
$0.0112.52%
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -33.34% | 174.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -51.24% | 68.59% | |||
| Operating Income | 51.24% | -68.59% | |||
| Income Before Tax | 52.72% | -87.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 52.72% | -87.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.09% | 58.90% | |||
| Net Income | 70.62% | -99.28% | |||
| EBIT | 51.24% | -68.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 71.43% | -96.00% | |||
| Normalized Basic EPS | 87.50% | -118.18% | |||
| EPS Diluted | 71.43% | -96.00% | |||
| Normalized Diluted EPS | 87.50% | -118.18% | |||
| Average Basic Shares Outstanding | 3.07% | 0.86% | |||
| Average Diluted Shares Outstanding | 3.07% | 0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||